|
[Evaluation of the therapeutic effectiveness of a
piracetam plus dihydroergocristine combination in the
treatment of vertigo]
Lopez Martinez R
Acta Otorrinolaringol Esp (Spain) Jul-Aug 1988, 39 (4)
p287-8.
No abstract.
[Treatment of vertigo syndrome with
Nootropil]
Miszke A; Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7.
No abstract.
The efficacy of piracetam in vertigo. A
double-blind study in patients with vertigo of central
origin.
Oosterveld WJ
Arzneimittelforschung (Germany, West) 1980, 30 (11)
p1947-9.
In a double-blind trial according to a switchback design
with 4 periods of one week each a comparison was made between
the effects of piracetam and a placebo. In 22 patients with
vertigo of central origin (posttraumatic, psychogenic,
ecileptogenic and hypertensive vertigo were excluded)
piracetam was found to significantly reduce symptoms. On
anamnestic examination the patients noted the effect of both
substances on vertigo, motility disturbances, vitality and
sleep. Piracetam was found to have a significant effect on the
first three. The effect of piracetam is explained by an
enhanced control of the cerebral cortex on the subordinated
vestibular centers, in agreement with findings in the
literature on animal and human pharmacology.
The balancing outcome of a pharmacological
treatment by vertiginous patients
Rocher F.P.
Dr. F.P. Rocher, Rotova 50, 46700 Gandia (Valencia)
Spain
Anales Otorrinolaringologicos Ibero-Americanos (Spain) 1999,
26/3 (271-291)
From the age of sixty, vertigo is mainly due to
vertebro-basilar insufficiency. It has been described that the
association of Dihydroergocristine-Piracetam (D-P) is a
usefull treatment for vertebro- basilar insufficiency. That is
why we have designed a comparative study between D-P an a
Placebo, so that prove if this association can be usefull in
the treatment of vertigo occassionated by cerebrovascular
insufficiency. Fifty patients complaining of vertigo were
included in the study after an untreatment term. 19 received a
daily capsule of Placebo, and the other 31, treated with D-P,
were divided in two groups: 16 patients received a dose of 3
mg Dihydroergocristine + 1,6 g Piracetam every 12 hours per
os; and 15 other were treated with 1,5 mg Dihydroergocristine
+ 0,8 g Piracetam every 8 hours during 90 days. The patients
were evaluated at the beginning of the study and 90 days
later, with anamnesis and vestibular tests. In the last
consultation the patients autoevaluated themselves the effect
and the tolerance to the drugs received. In the Placebo group
it was observed an improvement or disappearance of vertiginous
symptoms in the 68,5% of the cases, while with D-P was 93,7%
at the dose of 3 mg Dihydroergocristine + 1,6 Piracetam each
12 hours and 100% with the dose 1,5 mg Dihydroergocristine +
0,8 Piracetam each 8 hours. None of the treated patients with
D-P worsened their symptoms. We observe a considerable
decrease in the number of patients with vegetative symptoms in
the group treated with D-P related to the Placebo group,
though the symptoms persisted more time in the group treated
with D-P that in the Placebo group. The group treated with D-P
get a higher percentage of improvements and disappearance of
auditive and cervical symptoms that the group treated with
Placebo. In the vestibulo-spinal and cerebellous tests it was
observed a better improvement with D-P at the dose of 1,5 mg
of Dihydroergocristine + 0,8 g Piracetam each hours compared
with the other two groups. It can be concluded that the
association D-P is an effective treatment for vertigo, getting
also a higher normalization of the vestibular tests than
Placebo.
Dizziness and dizzy feeling in the elderly:
Treatment
Marquet T.; Belmin J.
J. Belmin, Serv. Medecine Interne Geriatrique, Hopital Rene
Muret-Bigottini, 93720 Sevran France
Revue de Geriatrie (France) 1997, 22/7 (457-462)
No abstract.
Disabling acute vertigo attack
Moussalle S.
Servicio de Otorrinolaringologia, Faculdade de Medicina,
Pontificia Universidade Catolica,Rio Grande Do Sul
Brazil
Revista Brasileira de Otorrinolaringologia (Brazil) 1994,
60/4 (326)
No abstract.
Vertigo
Gananca M.M.; Caovilla H.H.; Gananca F.F.; De Toledo Piza
Peluso E.
Rua Dr. A. de Campos Rodrigues, 309,CEP 04544-000, Sao Paulo
Brazil
Revista Brasileira de Medicina (Brazil) 1993/1994, 50/Spec.
Iss. Dec. (193-202)
The importance of the neurootological evaluation was
justified in order to establish the adequate diagnosis for the
adequate therapy. Very good results can be obtained in the
treatment of vertigo by the use of drugs, rehabilitation
exercises and nutritional diets. Surgery is indicated in some
particular cases.
Hemorheologic therapy of vertigo
Spurk P.; Dehnert H.G.; Angelkort B.
St. Vincenzkrankenhaus, D-5750 Menden 1 Germany
Vasa - Journal of Vascular Diseases (Switzerland) 1991,
20/Suppl. 33 (169-170)
Hemorheological treatment in vertigo. Depending on data of
hemorheology disturbances in risk factors and carotid artery
artherosclerosis-progression in vertigo on non-vestibular
origin this study evaluates treatment effects by basis, i.e.
correction of risk factors only, versus additional
hemorheological treatment (Lowering hct., HAES,
Pentoxifylline). Patients: N = 88 fe.51 m 37 age 25-86 mean
65.1. Results: ++ base gr. 35% hemorh. 62% + base gr. 40% hem.
38% no effect base gr. 25% hemorh. none.
Vertigo, dysarthria and hemiparesis in a 71
year-old woman
Vespignani H.; Defer G.; Gray F.
Service de Neurologie, Nancy France
Revue Neurologique (France) 1991, 147/11
(752-758)
No abstract.
Drugs for dizziniess; exploitation of medical
incapability
Van Gijn J.
Vakgroep Neurologie, Academisch Ziekenhuis, Postbus 85500,
3508 GA Utrecht Netherlands
Nederlands Tijdschrift voor Geneeskunde (Netherlands) 1991,
135/14 (599-603)
No abstract.
Vertigo syndrome treatment by nootropil
Miszke A.; Rapacz K.
Oddzial Otolaryngologiczny KSZ im G. Narutowicza, Krakow
Poland
Otolaryngologia Polska (Poland) 1988, 42/5
(312-317)
No abstract.
Clinic assay on the assocation piracetam and
dihydroergocristine in vertigo of several etiologies
Ordosgoitia H.; Castro C.; Carbayeda M.; Labella T.
Facultad de Medicina, Catedra de O.R.L., 15704 Santiago de
Compostela Spain
Anales Otorrinolaringologicos Ibero-Americanos (Spain) 1989,
16/3 (271-279)
No abstract.
Treatment of vertigo with piracetam: Comparison
with placebo in 50 cases
Haguenauer J.-P.
Gazette Medicale (France) 1986, 93/28 (67-70)
No abstract.
Current concepts in management
Oosterveld W.J.
Vestibular Department, Ear, Nose and Throat Clinic,
Academisch Medisch Centrum, Amsterdam Netherlands
Drugs (Australia) 1985, 30/3 (275-283)
Vertigo is not a disease, but a symptom. The management of
vertigo requires more than the treatment of the symptom alone,
as it concerns the whole physical and psychological condition
of the patient. In addition to causal treatment, symptomatic
treatment is needed in many cases. This specific treatment
consists of vestibular exercises and drug therapy. The
efficacy and use of the different drugs available are
discussed.
The effect of piracetam (Nootropil, UCB 6215) upon
the late symptoms of patients with head injuries
Aantaa E.; Meurman O.H.
Otolaryngol. Univ. Clin., Turku Finland
Journal of International Medical Research 1975, 3/5
(352-355)
Sixty patients whose head injuries had occurred 2-6 mth
previously were examined in a double blind trial to
demonstrate the effect of piracetam (UCB 6215) upon late
symptoms. A significantly better result of treatment of
vertigo was established in the piracetam group compared to the
placebo group. The disappearance of symptoms of vertigo could
also be objectively established by diminished spontaneous and
positional nystagmus as well as diminished pendel deviations
with eyes closed. No significant change during the period of
treatment could be established with respect to the caloric
test.
Piracetam in patients with chronic vertigo. Results
of a double-blind,placebo-controlled study
Rosenhall U.; Deberdt W.; Friberg U.; Kerr A.; Oosterveld
W.
UCB Pharma, International Development, Chemin du Foriest,
B-1420 Braine-l'Alleud Belgium
Clinical Drug Investigation (New Zealand), 1996, 11/5
(251-260)
The nootropic agent piracetam, which exerts diverse effects
through actions on cerebral neurotr reported to alleviate
vertigo. We performed a multicentre, double-blind,
placebo-controlled study to assess the efficacy and
tolerability of piracetam 800 mg 3 times daily orally for 8
weeks. The study group consisted of 143 middle-aged and
elderly outpatients of ear, nose and throat clinics who had
suffered from vertigo for at least 3 months, had experienced
at least 3 episodes per month, and the vertigo was severe
enough to disrupt daily life. Primary outcome measures were
patient self-evaluations of vertigo: the frequency of
episodes, and their severity using visual analogue scales
(VAS). Malaise and imbalance between episodes (VAS), the
effect of vertigo on walking (VAS), the duration of
incapacity, and overall evaluations by patients and
investigators were also assessed. On entry, episodes were more
frequent (p< 0.05) and malaise between episodes more severe
(p < 0.05) in the piracetam group. Data were not evaluable
in 54 patients because of either adverse events (12 piracetam,
12 placebo) or protocol deviations. An intention-to-treat
analysis showed that episodes of vertigo were less frequent (p
< 0.03) but not less severe on piracetam than on placebo:
interval malaise (p < 0.05) and imbalance (p < 0.01)
improved more and the duration of incapacity was less (p <
0.05). These changes, which were maximal after 8 weeks'
medication, had almost disappeared 4 weeks after the end of
treatment. Tolerance to piracetam was good, with few
drug-related adverse events occurring. These findings provide
further evidence that piracetam alleviates vertigo by reducing
the frequency of episodes, the severity of malaise and
imbalance between episodes, and the duration of associated
incapacity.
Nootropics: Efficacy and tolerability of products
from three active substance classes
Letzel H.; Haan J.; Feil W.B.
STATICON Medizinische, Forschunsgesellschaft mbH,
Behringstrasse 12, D-82152 Planegg Germany
Journal of Drug Development and Clinical Practice (United
Kingdom), 1996, 8/2 (77-94)
This paper reviews and evaluates all the currently
available clinical trials on the efficacy of three nootropics.
Only randomised, double-blind, placebo-controlled clinical
trials were taken into account which produced 44 studies
allowing comparison of the patient populations, efficacy and
tolerability of Ginkgo biloba special extracts, nimodipine and
tacrine. Taking all the studies together, statistically
significant results were obtained at three relevant levels of
efficacy (psychopathological, psychometric, behavioural) for
all three substances. Nine studies produced significant
results at all three efficacy levels. One study on Ginkgo
biloba and one on tacrine also produced significant
rerationalised diagnosis of dementia, inclusion of
mild-to-moderate cases, statistical proof at all three levels
of efficacy and global clinical evaluation). The clinical
efficacy of all three substances has thus been
demonstrated.
The effect of ginkgo biloba glycoside on the blood
viscosity and erythrocyte deformability
Erdincler D.S.; Karakoc Y.; Toplan S.; Onen S.; Sukyasyan A.;
Beger T.; Demiroglu C.
Gerontology Division, Department of Internal Medicine, I.U.
Cerrahpasa Medical Faculty, Istanbul Turkey
Clinical Hemorheology (USA), 1996, 16/3
(271-276)
In this study, we investigated the effect of
ginkgoglycoside in two different doses (19.2 mg/day and 28.8
mg/day) on blood viscosity and erythrocyte deformability in 27
patients suffering from cerebrovascular insufficiency. The
patients were divided into two groups randomly consisting of
13 and 14 patients respectively. Both groups received 28.8
mg/day ginkgoglycoside between the 1st and 15th day. The first
group received the same dose until the end of the 30th day,
whereas the dose administrated to the second group was reduced
to 19.2 mg/day. In the first group, during 30 days a
significant decrease in blood viscosity and a significant
increase in erythrocyte deformability were observed. In the
second group on the other hand, after dose reduction, the
effect of the drug on blood viscosity and erythrocyte
deformability were diminished. Improvement of symptoms
including vertigo, tinnutus, headache and forgetfulness in the
first group was found to be significantly different from the
2nd group at day 30 in a dose dependent manner.
[Clinical trial of the use of the combination of
piracetam and dihydroergocristine in vertigo from different
causes]
Ordosgoitia H, Castro C, Carbayeda M, Labella T
An Otorrinolaringol Ibero Am. 1989;16(3):271-9
We report on the therapeutic effect of a combination of
piracetam and dihydroergocristine in 55 vertiginous patients,
of both sexes, between 20 and 67 years of age, from different
causes (not scheduled for surgery). The trial lasted 3 months,
and the drugs were taken twice daily. Aside from one case who
stopped the drug therapy because of intolerance, the
conclusions drawn by the AA. are seemingly good, both
subjectively and objectively (audiometric and
electronystagmographic tracings).
[Treatment of vertigo syndrome with
Nootropil]
Miszke A, Rapacz K
Otolaryngol Pol (Poland) 1988, 42 (5) p312-7
No abstract.
The use of piracetam in vertigo.
Fernandes CM; Samuel J
S Afr Med J (South Africa) Nov 23 1985, 68 (11)
p806-8
A pilot study with piracetam (Nootropil; UCB) was performed
in 5 selected dizzy patients who had a diagnosis of
presbyvertigo or vertebrobasilar insufficiency. The study was
monitored by assessing the effect of piracetam on the
pursuit-tracking system. All patients showed a remarkable
improvement in their pursuit tracking, in addition to marked
subjective improvement in their vertigo.
The efficacy of piracetam in vertigo. A
double-blind study in patients with vertigo of central
origin.
Oosterveld WJ.
Arzneimittelforschung. 1980;30(11):1947-9.
In a double-blind trial according to a switchback design
with 4 periods of one week each a comparison was made between
the effects of piracetam and a placebo. In 22 patients with
vertigo of central origin (posttraumatic, psychogenic,
ecileptogenic and hypertensive vertigo were excluded)
piracetam was found to significantly reduce symptoms. On
anamnestic examination the patients noted the effect of both
substances on vertigo, motility disturbances, vitality and
sleep. Piracetam was found to have a significant effect on the
first three. The effect of piracetam is explained by an
enhanced control of the cerebral cortex on the subordinated
vestibular centers, in agreement with findings in the
literature on animal and human pharmacology.
Piracetam in the treatment of post-concussional
syndrome. A double-blind study.
Hakkarainen H; Hakamies L
Eur Neurol (Switzerland) 1978, 17 (1) p50-5
The effect of piracetam, a cyclical derivative of GABA, was
compared with that of a placebo in a double-blind study of 60
patients with post-concussional syndrome of 2-12 months'
duration. The daily dose of piracetam was 4,800 mg. After 8
weeks of treatment piracetam significantly reduced the
occurrence and severity of the following symptoms: vertigo,
headache, tiredness, decresed alertness, increased sweating
and neurasthenic symptoms. No significant effect was observed
on the following symptoms: tremor, orthostatic symptoms, and
memory disorders. Side effect were reported by 64% of the
patients under piracetam and by 32% under placebo. In the
author's opinion, piracetam seems to be a promising new drug
for the treatment of post-concussional syndrome.
[Evaluation of the therapeutic effectiveness of a
piracetam plus dihydroergocristine combination in the
treatment of vertigo]
Lopez Martinez R.
Acta Otorrinolaringol Esp. 1988
Jul-Aug;39(4):287-8.
No abstract.
[Hydergine in pathology of the inner ear]
Jimenez-Cervantes Nicolas J, Amoros Rodriguez LM
An Otorrinolaringol Ibero Am (1990) 17(1):85-98
There have been treated a total of 20 patients with
troubles on the cochlear compartment and/or vestibular level
which have been clinically expressed by a perceptive
hypoacusia, tinnitus and rotatory vertigo. The final
evaluation is referred to 17 patients, since three patients do
not appear for control. All patients were treated only with
Hydergine, on doses of 30 drops thrice daily, which is the
equivalent to 4.5 mg/day of active substance. This treatment
remained unaltered till the end of the last control. Controls
have been effected after 30, 60 and 90 days of starting the
treatment. In each control there was evaluated the subjective
improvement of vertigo, tinnitus and hypoacusia when effecting
to all patients by means of liminar- supraliminar- and
automaticaudiometry, impedancimetry, T one-decay-test and
electrooculonistagmography. The most meliorated symptomatology
was vertigo, with a global improvement of 93.7 per cent on the
treated patients. Tinnitus improve by 57.1 per cent and
hypoacusia by 20 per cent. There is a total correspondence
between the subjective data furnished by the patients and the
objective tests carried out in the successive controls.
[The elimination of chemotherapy side effects in
pulmonary tuberculosis patients]
Bal'tseva LB; Mel'nik GV; Man'ko VP
Vrach Delo (USSR) Apr 1990, (4) p71-3
Neurotoxic side-effects of tuberculosis chemotherapy
occurred in 14.9% of patients with tuberculosis treated
prophylactically with intramuscular pyridoxine infusions. Use
of small doses of nootropil (piracetam) allowed to control the
side-effects (headache and vertigo, sleep disorders,
irritation, memory disorders) and to continue treatment with
isoniazide, one of the most potent tuberculostatic agents.
The treatment of minocycline-induced brainstem
vertigo by the combined administration of piracetam and
ergotoxin.
Claussen CF, Schneider D, Patil NP
Acta Otolaryngol Suppl (Stockh). 1989;468:171-4.
Two randomized studies to test the efficacy of a
combination of Piracetam and Ergotoxin on the destabilized
brainstem are reported. In the first study, a pharmacological
model using Minocycline is employed. A follow-up clinical
study analysed the effect of the preparation in 5 patients
suffering from vertigo and other related complaints. It was
seen that there was a significant improvement in the nystagmus
profiles of the pharmacological model volunteers. Similarly,
the patient group showed a marked improvement in symptoms, and
in orientation capability as tested by
Cranio-Corpo-Graphy.
|